CN106074579A - The application in the medicine of preparation treatment diseases associated with inflammation of a kind of phenylpropanoids - Google Patents
The application in the medicine of preparation treatment diseases associated with inflammation of a kind of phenylpropanoids Download PDFInfo
- Publication number
- CN106074579A CN106074579A CN201610153537.0A CN201610153537A CN106074579A CN 106074579 A CN106074579 A CN 106074579A CN 201610153537 A CN201610153537 A CN 201610153537A CN 106074579 A CN106074579 A CN 106074579A
- Authority
- CN
- China
- Prior art keywords
- inflammation
- medicine
- phenylpropanoids
- application
- diseases associated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to pharmaceutical technology field, disclose the application in the medicine of preparation treatment diseases associated with inflammation of a kind of phenylpropanoids.Described phenylpropanoids demonstrates and can suppress cellular inflammation factor TNF α, IL 1 β, the expressional function of IL 6, and then there is anti-inflammatory activity, for diseases associated with inflammation, the exploitation such as the medicine of the diseases such as cervicitis, endometritis, pelvic inflammatory disease, mastitis, pharyngolaryngitis and/or arthritis provides direction.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of phenylpropanoids medicine at preparation treatment diseases associated with inflammation
Application in thing.
Background technology
The constituent structure extracting isolated from natural drug is various, active significantly, and it is carried out isolated and purified, structure
Modify, transform and complete synthesis, an always main thought of new drug development.
TNF-α: be a kind of can direct killing tumor cell and to normal cell without the cytokine of overt toxicity, be so far
One of bioactie agent that the direct killing function of tumor that found till the present is the strongest, but its toxic and side effects is the tightest
Weight.
IL-1 β: collaborative APC and the T cell activation of stimulating, promotion B cell proliferation and secretory antibody when local low concentration, enter
Row immunomodulating.There is endocrine effect during a large amount of generation: induced liver acute phase protein synthesizes, cause heating and cachexia.
IL-6: mankind's IL-6 gene is positioned on No. 7 chromosome；IL-6 molecular weight is between 21～30KD.Main by list
Core macrophage, Th2 cell, vascular endothelial cell, fibroblast produce.Activating B cell can be stimulated to breed, and secretion is anti-
Body；Stimulate T cell propagation and CTL activation；Cell cultured supernatant synthesized acute phase albumen, participates in inflammatory reaction；Promote that hemocyte is sent out
Educate.
IL-6 can be synthesized by various kinds of cell, including activation T cell and B cell, monocytes/macrophages, endotheliocyte,
Epithelial cell and fibroblast etc..The target cell of IL-6 effect is a lot, thin including macrophage, hepatocyte, static T
Born of the same parents, the B cell of activation and plasma cell etc.；Its biological effect is the most sufficiently complex.
Therefore, seek new compound, to suppress cellular inflammation factor TNF-α, the expressional function of IL-1 β, IL-6, should
For the treatment of diseases associated with inflammation, it is necessary.
Radix Flemingiae Philippinensis medical material is that pulse family (Leguminosae) Moghania (Flemingl.Roxb. or Moghania) is planted
Thing Flemingia macrophylla (Moghania macrophylla(Willd.) O.Kuntze) dry root, be mainly distributed in China
In region of Southeast.This plant is in Chinese Plants will (1995,41:313), TaiWan, China flora (1977,3:258), sea
South flora (1965,2:311), " Chinese Higher plant illustrated handbook " (1972,2:510), China main plant figure say (1955,
Pp707) and Guangzhou flora (1956, pp361) is all included.Radix Flemingiae Philippinensis medical material is the genuine medicinal materials of Guangxi province, history
It is loaded in " Zhiwu Mingshi Tukao ", has medication the most among the people basis.Its nature and flavor are sweet, micro-puckery, flat, have the merits such as removing damp-heat
Effect, is mainly used in treating rheumatic ostalgia, traumatic injury, chronic nephritis, dysmenorrhea and the gynaecopathia such as leucorrhea is many.This medical material is the most
Record into version " Chinese Pharmacopoeia " annex in 2005.
The composition that Flemingia macrophylla has been reported mainly has flavonoid, steroid, terpenoid, Anthraquinones, volatile oil composition, all has
Having certain pharmacologically active, its pharmacologically active is various, reports the more neuroprotective that has, and antiinflammatory, antioxidation, to disease
The anthelmintic action of pathogenic microorganism, parahormone effect, cytotoxicity, antibacterial action and immunological enhancement, antifatigue effect.
Radix Flemingiae Philippinensis is now widely used for the Chinese patent medicine of the type such as gynecological, rheumatic arthralgia and produces, such as FUKE QIANJIN PIAN, gynecological
A thousand pieces of gold capsule, JINJI CHONGJI, JINJI JIAONANG etc., this type of Chinese patent medicine is mainly used in gynaecopathia, and (dysmenorrhea, cold uterus be infertile, uterus
Sagging, pelvic inflammatory disease, mastitis, leucorrhea are many, blood deficiency in puerperal, arthralgia, waist and knee in puerperal, hypogalactia and breast ulcer etc.), weak anemia
(woman anemia, deficient qi and blood and the after being ill deficiency of vital energy etc.).In recent years, what clinical report was more is that FUKE QIANJIN PIAN is scorching in treatment gynecological
Effect in terms of disease.
At present, in the document of Radix Flemingiae Philippinensis, the document of report phenylpropanoids is few, finds effective Phenylpropanoid Glycosides class
Noval chemical compound, carries out isolated and purified, structural modification and synthesis, developing new drug to it, is applied to the treatment of diseases associated with inflammation, meaning
Great.
Summary of the invention
The technical problem to be solved in the present invention is, finds a kind of effective ingredient, and it can suppress cellular inflammation factor TNF-α,
The expressional function of IL-1 β, IL-6, can apply in the medicine of preparation treatment diseases associated with inflammation.The present invention provides a kind of Phenylpropanoid Glycosides
Compounds, it can suppress cellular inflammation factor TNF-α, the expressional function of IL-1 β, IL-6, and then have anti-inflammatory activity, for
The exploitation of anti-inflammatory drug provides direction, is used for treating related inflammation disease, such as cervicitis, endometritis, pelvic inflammatory disease, mammary gland
Inflammation, pharyngolaryngitis and/or arthritis etc..
It is an object of the invention to provide the medical applications of a kind of phenylpropanoids.
There is provided a kind of phenylpropanoids as the application in the medicine of preparation treatment diseases associated with inflammation, described Phenylpropanoid Glycosides
The structural formula of compounds is as shown in formula I:
(I).
Preferably, described phenylpropanoids is at preparation suppression cellular inflammation factor TNF-α, and IL-1 β, IL-6 express
Medicine in application, be applied to treat diseases associated with inflammation medicine in.
Preferably, described diseases associated with inflammation is cervicitis, endometritis, pelvic inflammatory disease, mastitis, pharyngolaryngitis and/or pass
Joint inflammation.
Described pharmaceutical pack contains the adjuvant and/or carrier pharmaceutically allowed.
Preferably, described medicine is possibly together with other active ingredient.
Preferably, described medicine is possibly together with in Radix Rosae Laevigatae, Fructus Zanthoxyli Dissiti, Caulis Spatholobi, Caulis Mahoniae, Herba Andrographis, Radix Angelicae Sinensis, Radix Codonopsis
One or more.
Preferably, described medicine is possibly together with in Radix Rosae Laevigatae, Fructus Zanthoxyli Dissiti, Caulis Spatholobi, Caulis Mahoniae, Herba Andrographis, Radix Angelicae Sinensis, Radix Codonopsis
The extract of one or more.
Described extract for press patent announcement CN1078079C, CN1170549C, CN1158087C, CN1330335C,
Carrying described in any one of CN1296071C, CN1321631C, CN1296072C, CN1296073C or several patent documents
Access method prepares.
The dosage form of described medicine is tablet, capsule, powder, granule, pill, solution, suspensoid, syrup, note
Penetrate agent, ointment, suppository or spray.
It is an object of the invention to from traditional prescriptions of Chinese medicine, by the prescription from FUKE QIANJIN PIAN and FUKE QIANJIN JIAONANG
In, prepare a kind of noval chemical compound by solvent extraction, column chromatography for separation, preparation liquid phase separation, purification, and experiments prove that,
It can apply to diseases associated with inflammation, such as cervicitis, endometritis, pelvic inflammatory disease, mastitis, pharyngolaryngitis and/or arthritis etc.
The treatment of disease.
Specifically, inventor by from FUKE QIANJIN PIAN, FUKE QIANJIN JIAONANG prescription, choose the dry of Flemingia macrophylla
Dry, by solvent extraction, column chromatography for separation, preparation liquid phase separation, purification, obtain phenylpropanoids of the present invention,
Then this compound is carried out test cell line, measure it to cellular inflammation factor TNF-α, the suppression degree of IL-1 β, IL-6, reality
Test and show, this compound in the range of concentration (7.50 13.50 μ g/mL), LPS is stimulated the Raw264.7 cellular inflammation that causes because of
Sub-TNF-α content has obvious inhibitory action (p ＜ 0.05), and shows obvious dose-dependence；In concentration 13.50
Under μ g/mL, inflammatory factor IL-1 β content is had obvious inhibitory action (p ＜ 0.05)；At concentration (10.50 13.50 μ g/mL)
In the range of inflammatory factor IL-6 content is all had obvious inhibitory action (p ＜ 0.05), show obvious dose-dependence.
Beneficial effects of the present invention:
The present invention is square degree at Chinese medicine, extracts, divides from Chinese medicine FUKE QIANJIN PIAN, FUKE QIANJIN JIAONANG
Obtaining a kind of phenylpropanoids from, purification, the experiment proved that, this compound demonstrates and can suppress the cellular inflammation factor
TNF-α, the expressional function of IL-1 β, IL-6, for diseases associated with inflammation, such as cervicitis, endometritis, pelvic inflammatory disease, mastitis, pharynx
The exploitation of the medicine of the disease such as laryngitis and/or arthritis provides direction.
The new Phenylpropanoid Glycosides compound structure that the present invention provides is simple, purity is high, and extraction separation method is easy, be prone to close
Become, be suitable for the commercial application of new drug.
Accompanying drawing explanation
Fig. 1 is the hydrogen nuclear magnetic resonance spectrogram of phenylpropanoids of the present invention.
Fig. 2 is the carbon-13 nmr spectra figure of phenylpropanoids of the present invention.
Fig. 3 is that phenylpropanoids of the present invention affects figure to cytoactive.
Fig. 4 is the phenylpropanoids of the present invention inhibitory action figure to NO.
Fig. 5 is the phenylpropanoids of the present invention inhibitory action figure to TNF-α.
Fig. 6 is the phenylpropanoids of the present invention inhibitory action figure to IL-1 β.
Fig. 7 is the phenylpropanoids of the present invention inhibitory action figure to IL-6.
Fig. 8 is the phenylpropanoids of the present invention inhibitory action figure to OH.
Detailed description of the invention
Further illustrate the present invention below in conjunction with Figure of description and specific embodiment, but embodiment is not to the present invention
Limit in any form.Unless stated otherwise, the present invention uses reagent, method and apparatus are the examination of the art routine
Agent, method and apparatus.Unless stated otherwise, to be the art conventional commercial former for raw material used by the present embodiment and equipment
Material and equipment.
The compound of the present invention is the phenylpropanoids shown in described formula I.This compound can use the present invention
The method extracted for raw material with Flemingia macrophylla provided prepares, it is also possible to adopts according to the structural formula combination that the present invention provides
Prepare by methods such as the chemosynthesis of this area.
The compounds of this invention, can be used as such as cervicitis, endometritis, pelvic inflammatory disease, mastitis, pharyngolaryngitis and/or joint
The medicine of the diseases associated with inflammation such as inflammation.
The compounds of this invention can be used as pharmaceutical composition together with the adjuvant pharmaceutically allowed and/or carrier, it is also possible to
In the case of adding the adjuvant that pharmaceutically allows and/or carrier with Radix Rosae Laevigatae, Fructus Zanthoxyli Dissiti, Caulis Spatholobi, Caulis Mahoniae, Herba Andrographis,
One or more Chinese crude drugs or the combination of extract in Radix Angelicae Sinensis, Radix Codonopsis are used as pharmaceutical composition, and the compounds of this invention is all right
Pharmaceutical composition it is used as together with other pharmaceutically acceptable active ingredient.
As pharmaceutical composition, can be tablet, capsule, powder, granule, pill, solution, suspensoid, syrup
Agent, injection, ointment, suppository, spray etc..
Further, tablet can be the sugar-coat made in the case of adding the adjuvant and/or carrier pharmaceutically allowed
Sheet, Film coated tablets, enteric coatings ply or two-ply, multilayer tablet.
Adjuvant and/or the carrier of the present invention can be such that
Make solid preparation, it is possible to use additive, such as sucrose, lactose, cellulose sugar, maltose alcohol, glucose, starch
Class, agar, alginates, chitin, chitosan class, pectin class, Radix Acaciae senegalis class, gelatin class, collagen class, casein,
Albumin, calcium phosphate, Sorbitol, glycine, glycerol, Polyethylene Glycol, sodium bicarbonate, Talcum etc..
Make semi-solid preparation, it is possible to use of animal or plant nature oils and fats (olive oil, Semen Maydis oil, Oleum Ricini etc.), mineral oil
Fat (vaseline, white vaseline, solid paraffin etc.), wax class (Jojoba oil, Brazil wax, Cera Flava etc.), partial synthesis or complete
The fatty acid glyceride (lauric acid, myristic acid, Palmic acid etc.) etc. of synthesis.
Make liquid preparation, can use additive, such as sodium chloride, glucose, Sorbitol, glycerol, olive oil, the third two
Alcohol, ethanol etc..In the case of especially making injection, it is possible to use aseptic aqueous solution, such as normal saline, isotonic solution, oiliness
Liquid, such as Oleum Sesami, soybean oil.Furthermore it is also possible to as required, and with suitable suspending agent, such as sodium carboxymethyl cellulose, nonionic
Surfactant, cosolvent, such as benzyl benzoate, benzyl alcohol etc..
The amount of the effective ingredient of these preparations is 0.01 ~ 80 weight % of preparation, is suitably 1 ~ 50 weight %, dosage according to
The symptom of patient, body weight, age etc. are different and change.
The preparation of embodiment 1 phenylpropanoids
The present embodiment provides a kind of preparation method of phenylpropanoids shown in formula I, comprises the steps:
S1. take Flemingia macrophylla 50kg, with root as raw material, be dried, be cut into small pieces.Alcohol reflux 3 through 8 times amount 60%
Secondary, each 2 hours, extracting solution is merged, is concentrated into without alcohol taste, obtains extractum standby；
S2. the extractum after concentrating in step S1 is dissolved in 10L water, uses D101 macroporous adsorptive resins that it is carried out eluting,
Eluant is water, 3 column volumes of eluting, collection eluent, and named MM-1 is standby；
S3. with anti-phase ODS column chromatography, the flow point MM-1 collected in step S2 being carried out eluting, eluant is methanol-water system,
Its volume ratio is 25:75,18 column volumes of eluting, collects the eluent of a flow point by every 3 column volumes, collects 6 in order
Individual flow point, is respectively designated as: MM-11, MM-12, MM-13, MM-14, MM-15, MM-16 are standby；
S4. by the flow point MM-12 collected in step S3 with preparing liquid phase separation, preparative liquid chromatography post is: YMC, 20mm*
250mm, flow velocity: 5ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 25:75:0.01,
Collect eluent by peak sequence, collect 7 flow points altogether, be respectively designated as MM-121, MM-122, MM-123, MM-124, MM-
125, MM-126, MM-127, standby；
S5. being purified with preparing liquid phase by the flow point MM-122 collected in step S4, preparative liquid chromatography post is: YMC, 20mm*
250mm, flow velocity: 5ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 15:85:0.01,
Collect eluent, after recrystallization, obtain described phenylpropanoids.
The preparation of embodiment 2 phenylpropanoids
The present embodiment provides a kind of preparation method of phenylpropanoids shown in formula I, comprises the steps:
S1. take Flemingia macrophylla 40kg, with root as raw material, be dried, be cut into small pieces.Alcohol reflux 2 through 6 times amount 50%
Secondary, each 1 hour, extracting solution is merged, is concentrated into without alcohol taste, obtains extractum standby；
S2. the extractum after concentrating in step S1 is dissolved in 5L water, uses D101 macroporous adsorptive resins that it is carried out eluting, washes
De-agent is ethanol and the volume ratio of water is 15:85,3 column volumes of eluting, collects eluent, and named MM-1 is standby；
S3. with anti-phase ODS column chromatography, the flow point MM-1 collected in step S2 being carried out eluting, eluant is methanol-water system,
Its volume ratio is 20:80,18 column volumes of eluting, collects the eluent of a flow point by every 3 column volumes, collects 6 in order
Individual flow point, is respectively designated as: MM-11, MM-12, MM-13, MM-14, MM-15, MM-16 are standby；
S4. by the flow point MM-12 collected in step S3 with preparing liquid phase separation, preparative liquid chromatography post is: YMC, 20mm*
250mm, flow velocity: 10ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 35:65:
0.01, collect eluent by peak sequence, collect 7 flow points altogether, be respectively designated as MM-121, MM-122, MM-123, MM-
124, MM-125, MM-126, MM-127, standby；
S5. being purified with preparing liquid phase by the flow point MM-122 collected in step S4, preparative liquid chromatography post is: YMC, 20mm*
250mm, flow velocity: 5ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 15:85:0.01,
Collect eluent, after recrystallization, obtain described phenylpropanoids.
The preparation of embodiment 3 phenylpropanoids
The present embodiment provides a kind of preparation method of phenylpropanoids shown in formula I, comprises the steps:
S1. take Flemingia macrophylla 60kg, with root as raw material, be dried, be cut into small pieces.The alcohol reflux of 7 times amount 70% 4 times,
Each 3 hours, extracting solution is merged, is concentrated into without alcohol taste, obtains extractum standby；
S2. the extractum after concentrating in step S1 is dissolved in 8L water, uses D101 macroporous adsorptive resins that it is carried out eluting, washes
De-agent is ethanol and the volume ratio of water is 10:90,3 column volumes of eluting, collects eluent, and named MM-1 is standby；
S3. with anti-phase ODS column chromatography, the flow point MM-1 collected in step S2 being carried out eluting, eluant is methanol-water system,
Its volume ratio is 30:70,18 column volumes of eluting, collects the eluent of a flow point by every 3 column volumes, collects 6 in order
Individual flow point, is respectively designated as: MM-11, MM-12, MM-13, MM-14, MM-15, MM-16 are standby；
S4. by the flow point MM-12 collected in step S3 with preparing liquid phase separation, preparative liquid chromatography post is: YMC, 20mm*
250mm, flow velocity: 10ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 30:70:
0.01, collect eluent by peak sequence, collect 7 flow points altogether, be respectively designated as MM-121, MM-122, MM-123, MM-
124, MM-125, MM-126, MM-127, standby；
S5. being purified with preparing liquid phase by the flow point MM-122 collected in step S4, preparative liquid chromatography post is: YMC, 20mm*
250mm, flow velocity: 5ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 15:85:0.01,
Collect eluent, after recrystallization, obtain described phenylpropanoids.
The preparation of embodiment 4 phenylpropanoids
The present embodiment provides a kind of preparation method of phenylpropanoids shown in formula I, comprises the steps:
S1. take Flemingia macrophylla 50kg, with root as raw material, be dried, be cut into small pieces.The alcohol reflux of 8 times amount 60% 2 times,
Each 1.5 hours, extracting solution is merged, is concentrated into without alcohol taste, obtains extractum standby；
S2. the extractum after concentrating in step S1 is dissolved in 6L water, uses D101 macroporous adsorptive resins that it is carried out eluting, washes
De-agent is ethanol and the volume ratio of water is 5:95,3 column volumes of eluting, collects eluent, and named MM-1 is standby；
S3. with anti-phase ODS column chromatography, the flow point MM-1 collected in step S2 being carried out eluting, eluant is methanol-water system,
Its volume ratio is 25:75,18 column volumes of eluting, collects the eluent of a flow point by every 3 column volumes, collects 6 in order
Individual flow point, is respectively designated as: MM-11, MM-12, MM-13, MM-14, MM-15, MM-16 are standby；
S4. by the flow point MM-12 collected in step S3 with preparing liquid phase separation, preparative liquid chromatography post is: YMC, 20mm*
250mm, flow velocity: 10ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 25:75:
0.01, collect eluent by peak sequence, collect 7 flow points altogether, be respectively designated as MM-121, MM-122, MM-123, MM-
124, MM-125, MM-126, MM-127, standby；
S5. being purified with preparing liquid phase by the flow point MM-122 collected in step S4, preparative liquid chromatography post is: YMC, 20mm*
250mm, flow velocity: 5ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 15:85:0.01,
Collect eluent, after recrystallization, obtain described phenylpropanoids.
The preparation of embodiment 5 phenylpropanoids
The present embodiment provides a kind of preparation method of phenylpropanoids shown in formula I, comprises the steps:
S1. take Flemingia macrophylla 50kg, with root as raw material, be dried, be cut into small pieces.The alcohol reflux of 8 times amount 80% 2 times,
Each 1.5 hours, extracting solution is merged, is concentrated into without alcohol taste, obtains extractum standby；
S2. the extractum after concentrating in step S1 is dissolved in 6L water, uses D101 macroporous adsorptive resins that it is carried out eluting, washes
De-agent is ethanol and the volume ratio of water is 10:90,3 column volumes of eluting, collects eluent, and named MM-1 is standby；
S3. with anti-phase ODS column chromatography, the flow point MM-1 collected in step S2 being carried out eluting, eluant is methanol-water system,
Its volume ratio is 28:72,18 column volumes of eluting, collects the eluent of a flow point by every 3 column volumes, collects 6 in order
Individual flow point, is respectively designated as: MM-11, MM-12, MM-13, MM-14, MM-15, MM-16 are standby；
S4. by the flow point MM-12 collected in step S3 with preparing liquid phase separation, preparative liquid chromatography post is: YMC, 20mm*
250mm, flow velocity: 10ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 10:90:
0.01, collect eluent by peak sequence, collect 7 flow points altogether, be respectively designated as MM-121, MM-122, MM-123, MM-
124, MM-125, MM-126, MM-127, standby；
S5. being purified with preparing liquid phase by the flow point MM-122 collected in step S4, preparative liquid chromatography post is: YMC, 20mm*
250mm, flow velocity: 5ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 15:85:0.01,
Collect eluent, after recrystallization, obtain described phenylpropanoids.
Compound embodiment 1 to embodiment 5 prepared carries out mass spectrum, proton nmr spectra, carbon-13 nmr spectra
Detection, result prove gained compound be: 4-glucosyl group-11-methyl-8,9-benzene hexene.Its structural formula such as formula I institute
Show:
(I).
Its mass spectrum, proton nmr spectra, carbon-13 nmr spectra spectral data as follows:
HR-ESIMS shows [M+Na]+for m/z 375.1984, and in conjunction with nuclear-magnetism feature, can obtain molecular formula is C19H28O6, unsaturated
Degree is 6.
1H-NMR (600 MHz, CD3OD): 6.89 (d,J=1.8 Hz, 2H), 5.82 (d,J = 1.8Hz, 2H),
4.94 (d,J=7.6Hz, 1H), 4.86 (d, 2H), 2.71 (t,J=7.0 Hz, 2H), 2.44 (t,J=7.0 Hz,
2H),2.40(s, 3H), 1.95 (m,1H),1.17(s,3H),3.30-4.00 (glc-H)。
13C-NMR (150MHz, CD3OD): 141.4 (C-4),130.2(C-1), 119.6(C-2), 115.4 (C-
3), 114.4(C-5),111.3(C-6),101.3(C-1'),109.3(C-9),102.5(C-8),61.5-77.8(C2''-
C6''),45.0(C-7),28.8(C-10),18.7(C-11),17.3(C-12),14.5(-CH3)。
Experimental example 6 application test
RAW 264.7 oxidative macrophage that LPS is induced by compound of the present invention stress be with the impact of inflammation.(for reality
During testing, record is convenient, is numbered by the phenylpropanoids shown in formula I of the present invention below: medicine MM-122, i.e. originally
Medicine MM-122 described in invention i.e. refers to phenylpropanoids shown in formula I of the present invention.)
1 materials and methods
1.1 medicines and instrument
Lipopolysaccharide (lipopolysaccharide, LPS), MTT is purchased from Sigma company；Mouse macrophage Raw 264.7 purchases
The refined cell bank from Hunan；PBS；DMEM high glucose medium, hyclone, penicillin and streptomycin；Full-automatic microplate reader；Constant temperature CO2
Incubator.
Mice IL-1β (IL-1-β) ELISA detection kit, lot number: 2014/06 (96T)；Little mIL6
(IL-6) ELISA detection kit, lot number: 2014/06 (96T)；Murine tumor necrosis factor-α (TNF-α) ELISA detects examination
Agent box, lot number: 2014/06 (96T)；Mouse nitrous oxide (NO) ELISA detection kit, lot number: 2014/10 (96T)；Little
Mus hydroxyl radical free radical (OH) ELISA detection kit, lot number: 2014/10 (96T).
Prepared by 1.2 medicines
First dissolve with a small amount of DMSO, be then diluted to certain concentration with DMEM, make DMSO content in final concentration be less than 1 ‰.
1.3 cells are cultivated
Mouse macrophage Raw 264.7 is incubated at containing 10% heat the inactivation hyclone (FBS) of (56 DEG C, 30min), 10U/mL
Penicillin sodium, 100 μ g/mL streptomycins DMEM culture medium in, 37 DEG C, 5%CO2Constant incubator is hatched growth.
1.4 cell viabilities measure
Cell viability is measured by mtt assay.Cell is made cell suspension inoculation hatch in 96 orifice plates (1 × 104/hole)
24h, resynchronization 24h, then act on cell 2h by the medicine of variable concentrations, and then adding LPS (30 μ g/mL) stimulates
24h, inhales and abandons former culture medium, and every hole adds the MTT (0.5mg/mL) of 100 μ L and continues to hatch 4h, inhales and abandons culture medium, and every hole adds
The DMSO of 150 μ L, shaking table shaking 10min, measure absorbance at 490nm.
1.5 NO assays
Raw 264.7 cell is inoculated in 96 orifice plate 24h, resynchronization 24h, then the medicine of variable concentrations is acted on cell
2h, then adds LPS(30 μ g/mL) stimulate 24h, finally collect supernatant, and be centrifuged 5min, subpackage supernatant in 10000rpm
It is placed in-80 DEG C to save backup.By mice NO kit measurement NO content.
1.6 inflammatory factor TNF-α, IL-1 β, IL-6 measure
Sample takes 1.5 samples prepared for subsequent inflammation factor determination.Cell produces TNF-α, the amount of IL-1 β, IL-6
By mice TNF-α, IL-1 β, IL-6 test kit measures.
1.7 OH assays
Sample takes 1.5 samples prepared for OH factor determination.By OH kit measurement content.
1.8 statistical analysis
Using SPSS17.0 software, experimental data represents with x ± s；The data obtained is by by one factor analysis of variance, homogeneity of variance
Checking with LSD, heterogeneity of variance Dunnett T3 checks.
2 experimental results
2.1 cell viability
The impact of cell viability is evaluated by medicine by mtt assay.As it is shown on figure 3, medicine MM-122 is at 1.50-13.50 μ g/mL
In concentration range, Raw 264.7 cell viability is had no significant effect；Therefore the drug level under this range of concentrations is for rear
Continuous experiment is suitable.
The generation of 2.2 Drug inhibition NO
As shown in Figure 4, stimulating Raw 264.7 cell by LPS, it produces NO (65.81 ± 2.93 IU/mL) content with normal
Group NO (33.61 ± 2.19IU/mL) compares significantly raised (p ＜ 0.01).The inflammation that LPS is caused under this concentration by medicine MM-122
In disease model, NO content is raised and there is no obvious inhibitory action.
2.3 Drug inhibition TNF-α, the generation of IL-1 β, IL-6
As shown in Figures 5 to 7, Raw 264.7 cell, Raw 264.7 cellular inflammation factor TNF-α are stimulated by LPS
(132.16 ± 5.28pg/mL), IL-1 β (358.80 ± 24.64 pg/mL), IL-6 (198.39 ± 5.97 pg/mL) contain
Amount and normal group TNF-α (65.41 ± 6.29 pg/mL), IL-1 β (172.67 ± 10.06pg/mL), IL-6 (103.34 ±
2.88pg/mL) compare content significantly raised (p ＜ 0.01)；Illustrate that LPS can stimulate Raw 264.7 cell to produce a large amount of inflammation
The factor.
LPS is stimulated Raw 264.7 cell caused scorching in the range of concentration (7.50-13.50 μ g/mL) by medicine MM-122
Inflammation factor TNF-α content has obvious inhibitory action (p ＜ 0.05), and shows obvious dose-dependence；In concentration
Under 13.50 μ g/mL, inflammatory factor IL-1 β content is had obvious inhibitory action (p ＜ 0.05)；At concentration (10.50-13.50 μ
G/mL) in the range of, inflammatory factor IL-6 content is had obvious inhibitory action (p ＜ 0.05), shows obvious dose-dependant and close
System.
The generation of 2.4 Drug inhibition OH
As shown in Figure 8, stimulating Raw 264.7 cell by LPS, it produces OH (113.58 ± 6.03 ng/mL) content with normal
Group OH (63.40 ± 1.19ng/mL) compares significantly raised (p ＜ 0.01).
The OH content that LPS is caused by medicine MM-122 at various concentrations raises does not has obvious inhibitory action.
This experiment, through In vitro culture, have studied medicine MM-122 to mouse macrophage NO, TNF-α, IL-1 β, IL-
6, the OH impacts generated.
Medicine MM-122 without obvious inhibiting effect, but significantly inhibits TNF-α to the generation of factor NO under middle and high concentration,
IL-1 β, IL-6 content, illustrate that it mainly affects is TNF-α, the approach of IL-1 β, IL-6, thus plays antiphlogistic effects,
It is obvious to OH unrestraint effect, illustrates that it is substantially without antioxidant activity.
Embodiment 7
The preparation of tablet: first prepare the phenylpropanoids shown in formula I as embodiment 1 method, by itself and excipient weight
Excipient, pelletizing press sheet is added than the ratio for 1:10.
Embodiment 8
The preparation of powder: first prepare the phenylpropanoids shown in formula I, routinely powder preparation method system as embodiment 1 method
Become powder.
Embodiment 9
Capsule or the preparation of granule: first prepare the phenylpropanoids shown in formula I as embodiment 1 method, by its with
Excipient weight adds excipient than the ratio for 1:10, makes capsule or granule.
Embodiment 10
The preparation of injection: first prepare the phenylpropanoids shown in formula I, routinely water for injection as embodiment 1 method,
Fine straining, injection is made in embedding sterilizing.
Embodiment 12
A kind of pharmaceutical composition, prepares the phenylpropanoids shown in formula I, and Radix Rosae Laevigatae, list containing embodiment 1 method
The powder that face pin, Caulis Spatholobi, Caulis Mahoniae, Herba Andrographis, Radix Angelicae Sinensis, Radix Codonopsis are made, and adjuvant.
Embodiment 13
A kind of pharmaceutical composition, prepares the phenylpropanoids shown in formula I, and Radix Rosae Laevigatae, list containing embodiment 1 method
Face pin, Caulis Spatholobi, Caulis Mahoniae, Herba Andrographis, Radix Angelicae Sinensis, the extract of Radix Codonopsis, and adjuvant.Extract is by patent announcement number
CN1078079C、CN1170549C、CN1158087C、CN1330335C、CN1296071C、CN1321631C、CN1296072C、
In any one of CN1296073C or several patent documents, extracting method prepares.
The ultimate principle of the present invention and principal character and the advantage of the present invention have more than been shown and described.The technology of this area
Personnel, it should be appreciated that the present invention is not restricted to the described embodiments, simply illustrating this described in above-described embodiment and description
The principle of invention, without departing from the spirit and scope of the present invention, the present invention also has various changes and modifications, and this is to this
Being apparent from for skilled person, these changes and improvements both fall within scope of the claimed invention.This
Bright claimed scope is defined by appending claims and equivalent thereof.
Claims (7)
1. a phenylpropanoids application in the medicine of preparation treatment diseases associated with inflammation, described phenylpropanoids
Structural formula as shown in formula I:
(I).
Apply the most according to claim 1, it is characterised in that be at preparation suppression cellular inflammation factor TNF-α, IL-1 β,
Application in the medicine that IL-6 expresses.
Apply the most according to claim 1, it is characterised in that described diseases associated with inflammation is cervicitis, endometritis, pelvic cavity
Inflammation, mastitis, pharyngolaryngitis and/or arthritis.
4. according to the application described in any one of claims 1 to 3, it is characterised in that described medicine contains pharmaceutically allow auxiliary
Material and/or carrier.
Application the most according to claim 4, it is characterised in that described medicine possibly together with Radix Rosae Laevigatae, Fructus Zanthoxyli Dissiti, Caulis Spatholobi,
One or more in Caulis Mahoniae, Herba Andrographis, Radix Angelicae Sinensis, Radix Codonopsis.
Application the most according to claim 4, it is characterised in that described medicine possibly together with Radix Rosae Laevigatae, Fructus Zanthoxyli Dissiti, Caulis Spatholobi,
The extract of one or more in Caulis Mahoniae, Herba Andrographis, Radix Angelicae Sinensis, Radix Codonopsis.
Application the most according to claim 4, it is characterised in that the dosage form of described medicine be tablet, capsule, powder,
Granule, pill, solution, suspensoid, syrup, injection, ointment, suppository or spray.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610153537.0A CN106074579B (en) | 2016-03-17 | 2016-03-17 | A kind of application of phenylpropanoids in the drug for preparing treatment diseases associated with inflammation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610153537.0A CN106074579B (en) | 2016-03-17 | 2016-03-17 | A kind of application of phenylpropanoids in the drug for preparing treatment diseases associated with inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106074579A true CN106074579A (en) | 2016-11-09 |
| CN106074579B CN106074579B (en) | 2018-09-25 |
Family
ID=58702312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610153537.0A Active CN106074579B (en) | 2016-03-17 | 2016-03-17 | A kind of application of phenylpropanoids in the drug for preparing treatment diseases associated with inflammation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106074579B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112999233A (en) * | 2019-12-19 | 2021-06-22 | 中国医学科学院药物研究所 | Monoterpene glycoside compounds from red peony root and preparation method and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101235059B (en) * | 2008-02-29 | 2011-05-18 | 重庆市中药研究院 | Phenylpropanoids derivatives, preparation method thereof and medical composition using the same as active component |
| CN104274578B (en) * | 2014-09-05 | 2017-12-26 | 株洲千金药业股份有限公司 | A kind of Chinese medicine composition with inhibiting bacteria and diminishing inflammation effect and preparation method thereof |
-
2016
- 2016-03-17 CN CN201610153537.0A patent/CN106074579B/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112999233A (en) * | 2019-12-19 | 2021-06-22 | 中国医学科学院药物研究所 | Monoterpene glycoside compounds from red peony root and preparation method and application thereof |
| CN112999233B (en) * | 2019-12-19 | 2023-10-20 | 中国医学科学院药物研究所 | Monoterpene glycoside compounds from red paeony root, preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106074579B (en) | 2018-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kokotkiewicz et al. | Isolation of xanthone and benzophenone derivatives from Cyclopia genistoides (L.) Vent.(honeybush) and their pro-apoptotic activity on synoviocytes from patients with rheumatoid arthritis | |
| CN106074579A (en) | The application in the medicine of preparation treatment diseases associated with inflammation of a kind of phenylpropanoids | |
| CN105663150B (en) | A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug for preparing treatment diseases associated with inflammation | |
| CN102366621B (en) | Plant estrogenic effect of acanthopanax biochemical traditional Chinese medicine compound extract and its application | |
| CN105777821B (en) | Phenylpropanoids and its pharmaceutically acceptable salt and pharmaceutical composition | |
| CN106046072B (en) | Phenylpropanoids and its pharmaceutically acceptable salt and pharmaceutical composition | |
| CN105708845B (en) | A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug for preparing treatment diseases associated with inflammation | |
| CN105732736B (en) | A kind of preparation method of phenylpropanoids | |
| CN105820197B (en) | A kind of phenylpropanoids and its pharmaceutical composition | |
| CN106046073B (en) | A kind of preparation method of phenylpropanoids | |
| CN105732737B (en) | A kind of phenylpropanoids and its pharmaceutical composition | |
| CN105582016B (en) | A kind of application of phenylpropanoids in the drug for preparing treatment diseases associated with inflammation | |
| CN105601681B (en) | A kind of preparation method of phenylpropanoids | |
| CN105601682B (en) | Phenylpropanoids and its pharmaceutically acceptable salt and pharmaceutical composition | |
| CN105687217B (en) | A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug of preparation treatment diseases associated with inflammation | |
| CN105646613B (en) | Phenylpropanoids and its pharmaceutically acceptable salt and pharmaceutical composition | |
| CN105693789B (en) | A kind of preparation method of phenylpropanoids | |
| CN105884841B (en) | A kind of preparation method of phenylpropanoids | |
| CN105646614B (en) | Phenylpropanoids and its pharmaceutically acceptable salt and pharmaceutical composition | |
| CN105663149B (en) | A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug for preparing treatment diseases associated with inflammation | |
| CN106074583B (en) | A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug for preparing treatment diseases associated with inflammation | |
| CN105669792B (en) | A kind of preparation method of phenylpropanoids | |
| CN106046071B (en) | A kind of preparation method of phenylpropanoids | |
| US10329316B2 (en) | Phenylpropanoid compound and preparation method and use thereof | |
| CN115025141B (en) | White dorsum Shemu total saponins and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |